<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703599</url>
  </required_header>
  <id_info>
    <org_study_id>Ad-003</org_study_id>
    <nct_id>NCT00703599</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes</brief_title>
  <official_title>Phase I/II Study of Intravenous Administration of Activated Autologous Adipose-Derived Stromal Vascular Fraction in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adistem Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adistem Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous administration of autologous
      adipose stem cells is safe and beneficial in patients with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes Mellitus is of large epidemic proportions worldwide. It is proliferating at such a
      fast rate that new novel drugs and other therapeutic approaches are required. The purpose of
      this Phase I/II study is to determine whether the intravenous administration of activated
      adipose-derived stromal vascular fraction as a single procedure is safe and efficacious in
      patients with Type 1 Diabetes Mellitus. Patients will be observed over 12 months following
      the procedure, with 2 weeks, 1 month and tri-monthly diagnostics and life style
      questionaires.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lowering of insulin-dependence and anti-hyperglycemic medication dosages</measure>
    <time_frame>At 2, 4, 12, 24, 36, and 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lowering of glycosylated hemoglobin (HbA1C).</measure>
    <time_frame>At 4, 12, 24, 36, and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increased circulating C-Peptide levels</measure>
    <time_frame>At 4, 12, 24, 36, and 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increased general well-being of patients.</measure>
    <time_frame>At 2, 4, 12, 24, 36, and 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No detrimental change seen in kidney function tests, liver function tests and other haematological parameters.</measure>
    <time_frame>At 2, 4, 12, 24, 36, and 48 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the only arm and that is the treatment group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Adipose-derived Stem cells</intervention_name>
    <description>Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Treatment Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of Type I diabetes for at least 2 years

          -  Insulin-dependent

        Exclusion Criteria:

          -  Presence of acute diabetic complications in the acute stage as recent myocardial
             infarction, recent CVA or acute renal failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emeritta A Barrenechea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterens Memorial Medical Centre, Philippines</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florencio Q Lucero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Philippines, College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Letitia Lucero-Palma, MD</last_name>
    <role>Study Director</role>
    <affiliation>Far Eastern University-NRMF Hospital, Quezon City, Philippines</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bill Paspaliaris, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Adistem Ltd, Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Letitia Lucero-Palma, MD</last_name>
    <phone>63-916-478-7512</phone>
    <email>lettielucero@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beverly Hills Medical Group</name>
      <address>
        <city>Makati City</city>
        <state>Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florencio Q Lucero, MD</last_name>
      <phone>63-917-896-6411</phone>
      <email>dr-flucero@pldtdsl.net</email>
    </contact>
    <investigator>
      <last_name>Florencio Q Lucero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterens Memorial Medical Centre</name>
      <address>
        <city>Quezon City</city>
        <state>Manila</state>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emerita A Barrenechea, MD</last_name>
      <phone>63-917-811-1008</phone>
      <email>emieab@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Emerita A Barrenechea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <reference>
    <citation>Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007 May 11;100(9):1249-60. Review.</citation>
    <PMID>17495232</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <last_update_submitted>June 28, 2008</last_update_submitted>
  <last_update_submitted_qc>June 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Bill Paspaliaris / Director</name_title>
    <organization>Adistem Ltd</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Adipose-derived stem cells</keyword>
  <keyword>Adipose stromal vascular fraction</keyword>
  <keyword>Autologous</keyword>
  <keyword>Insulin-dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

